Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

被引:60
作者
Gaedigk, A
Bhathena, A
Ndjountché, L
Pearce, RE
Abdel-Rahman, SM
Alander, SW
Bradford, LD
Leeder, JS
机构
[1] Childrens Mercy Hosp & Clin, Div Clin Pharmacol & Expt Therapeut, Kansas City, MO 64108 USA
[2] Morehouse Sch Med, Atlanta, GA 30310 USA
关键词
CYP2D6; SNPs; haplotype; dextromethorphan; African American;
D O I
10.1038/sj.tpj.6500305
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cytochrome P4502D6 (CYP2D6) genotyping reliably predicts poor metabolizer phenotype in Caucasians, but is less accurate in African Americans. To evaluate discordance we have observed in phenotype to genotype correlation studies, select African American subjects were chosen for complete resequencing of the CYP2D6 gene including 4.2 kb of the CYP2D7-2D6 intergenic region. Comparisons were made to a CYP2D6*1 reference sequence revealing novel SNPs in the upstream, coding and intervening sequences. These sequence variations, defining four functional alleles (CYP2D6* 41B, * 45A and B and * 46), were characterized for their ability to influence splice site strength, transcription level or catalytic protein activity. Furthermore, their frequency was determined in a population of 251 African Americans. A - 692(TGTG) deletion ( CYP2D6* 45B) did not significantly decrease gene expression, nor could any other upstream SNP explain a genotype-discordant case. CYP2D6* 45 and * 46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype.
引用
收藏
页码:173 / 182
页数:10
相关论文
共 41 条
[1]   Concordance between tramadol and dextromethorphan parent/metabolite ratios: The influence of CYP2D6 and non-CYP2D6 pathways on biotransformation [J].
Abdel-Rahman, SM ;
Leeder, JS ;
Wilson, JT ;
Gaedigk, A ;
Gotschall, RR ;
Medve, R ;
Liao, S ;
Spielberg, SP ;
Kearns, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (01) :24-29
[2]   Investigation of terbinafine as a CYP2D6 inhibitor in vivo [J].
Abdel-Rahman, SM ;
Gotschall, RR ;
Kauffman, RE ;
Leeder, JS ;
Kearns, GL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :465-472
[3]   Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden [J].
Aklillu, E ;
Herrlin, K ;
Gustafsson, LL ;
Bertilsson, L ;
Ingelman-Sundberg, M .
PHARMACOGENETICS, 2002, 12 (05) :375-383
[4]   Characterization of the human cytochrome P4502D6 promoter - A potential role for antagonistic interactions between members of the nuclear receptor family [J].
Cairns, W ;
Smith, CAD ;
McLaren, AW ;
Wolf, CR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (41) :25269-25276
[5]   A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype [J].
Chida, M ;
Yokoi, T ;
Nemoto, N ;
Inaba, M ;
Kinoshita, M ;
Kamataki, T .
PHARMACOGENETICS, 1999, 9 (03) :287-293
[6]   New allelic arrangement CYP2D6*36x2 found in a Japanese poor metabolizer of debrisoquine [J].
Chida, M ;
Ariyoshi, N ;
Yokoi, T ;
Nemoto, N ;
Inaba, M ;
Kinoshita, M ;
Kamataki, T .
PHARMACOGENETICS, 2002, 12 (08) :659-662
[7]   Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships [J].
Chou, WH ;
Yan, FX ;
Robbins-Weilert, DK ;
Ryder, TB ;
Liu, WW ;
Perbost, C ;
Fairchild, M ;
de Leon, J ;
Koch, WH ;
Wedlund, PJ .
CLINICAL CHEMISTRY, 2003, 49 (04) :542-551
[8]   Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians [J].
Droll, K ;
Bruce-Mensah, K ;
Otton, SV ;
Gaedigk, A ;
Sellers, EM ;
Tyndale, RF .
PHARMACOGENETICS, 1998, 8 (04) :325-333
[9]   Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects [J].
Gaedigk, A ;
Ndjountché, L ;
Gaedigk, R ;
Leeder, JS ;
Bradford, LD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :575-576
[10]   CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the-1584G promoter polymorphism [J].
Gaedigk, A ;
Ryder, DL ;
Bradford, LD ;
Lceder, JS .
CLINICAL CHEMISTRY, 2003, 49 (06) :1008-1011